are people dying from semaglutide Weight loss jabs: Two deaths reported to drug watchdog GLP-1 agonists like Ozempic may

Hanmi Pharmaceutical leads the pack Having completed Phase 3 clinical trials in Korea for Efpeglenatide, a weekly injectable GLP-1 drug, aiming for launch in the second half of 2026 Promises fewer side effects and added benefits like reduced cardiovascular and kidney risks Expected to be priced lower than imports like Wegovy, thanks to local production Also working on next-gen drugs: HM15275 shows faster, more effective weight loss than current drugs

The Wall Street Journal

Nano liposome glutathione, which is deeply absorbed into 0.002 micro particles the size of pores, provides a three-dimensional glow

Many people in Chennai search for an effective, safe solution that fits their budget

Addressing side effects promptly is essential for the success and comfort of your treatment

Is there a role for NAC